Buy & Sell Prologis Inc (PLD) – Prologis Inc Price Today
Aura AI Summary
Key Stats
- $130.50BMarket Cap
- Real EstateSector
- -5.9%3M Drawdown
- $164.37BEnterprise Value
- 3.06%Dividend Yield
- 99 daysTypical Hold Time
Prologis Inc (PLD) is currently valued at a market capitalization of $130.50B, with an enterprise value of $164.37B. Over the past 52 weeks, Prologis Inc has traded between a low of $104.08 and a high of $148.74, highlighting its annual price range. Over the past three months, Prologis Inc has recorded a drawdown of -5.9%, reflecting recent price volatility. Prologis Inc offers a dividend yield of 3.06%, with the most recent dividend of $1.07 paid on 16 Jun 26. On average, investors hold Prologis Inc for approximately 99 days, indicating typical investor behavior on the platform.
About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Most Recent News
State Street Global Advisors reduces stake in DCC plc below 1.4% with recent share sales.
State Street Global Advisors & Affiliates disclosed a reduction in their holdings of DCC plc ordinary shares to 1,193,218 shares, representing 1.39682% of the company. The reduction involved selling 1,544 shares at €62.30 each on June 26, 2026. This ...

Global head-up display market to nearly double to $13.7B by 2030, driven by digital cockpits and EV growth.
The global head-up display (HUD) market is expected to grow from $6.9 billion in 2024 to $13.7 billion by 2030, at a CAGR of 12.8%, fueled by rising demand for digital cockpits and advanced driver assistance systems in vehicles. Asia-Pacific leads wi...

Study shows 1 in 7 patients switch back to Humira after moving to biosimilars post-formulary changes
A new study analyzing nearly 68,000 US patients found that adoption of adalimumab biosimilars increased significantly after formulary changes, but over 16% of those who switched from Humira reverted back to the original drug. The research highlights ...
